Translational advances in pancreatic ductal adenocarcinoma therapy
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently
detected at advanced stages, limiting treatment options to systemic chemotherapy with …
detected at advanced stages, limiting treatment options to systemic chemotherapy with …
Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis
PURPOSE To analyze the prevalence of homologous recombination deficiency (HRD) in
patients with pancreatic ductal adenocarcinoma (PDAC). MATERIALS AND METHODS We …
patients with pancreatic ductal adenocarcinoma (PDAC). MATERIALS AND METHODS We …
Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer
SB Malla, RM Byrne, MW Lafarge, SM Corry… - Nature Genetics, 2024 - nature.com
Molecular stratification using gene-level transcriptional data has identified subtypes with
distinctive genotypic and phenotypic traits, as exemplified by the consensus molecular …
distinctive genotypic and phenotypic traits, as exemplified by the consensus molecular …
Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA–Associated Pancreatic Cancer in the Clinical and Preclinical Setting
C Stossel, M Raitses-Gurevich, D Atias, T Beller… - Cancer discovery, 2023 - AACR
Germline BRCA–associated pancreatic ductal adenocarcinoma (gl BRCA PDAC) tumors are
susceptible to platinum and PARP inhibition. The clinical outcomes of 125 patients with gl …
susceptible to platinum and PARP inhibition. The clinical outcomes of 125 patients with gl …
Precision medicine in pancreatic cancer: patient-derived organoid pharmacotyping is a predictive biomarker of clinical treatment response
TT Seppälä, JW Zimmerman, R Suri, H Zlomke… - Clinical Cancer …, 2022 - AACR
Purpose: Patient-derived organoids (PDO) are a promising technology to support precision
medicine initiatives for patients with pancreatic ductal adenocarcinoma (PDAC). PDOs may …
medicine initiatives for patients with pancreatic ductal adenocarcinoma (PDAC). PDOs may …
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
PA Konstantinopoulos, AABA da Costa… - Nature …, 2021 - nature.com
In a trial of patients with high grade serous ovarian cancer (HGSOC), addition of the ATR
inhibitor berzosertib to gemcitabine improved progression free survival (PFS) compared to …
inhibitor berzosertib to gemcitabine improved progression free survival (PFS) compared to …
RP-3500: a novel, potent, and selective ATR inhibitor that is effective in preclinical models as a monotherapy and in combination with PARP inhibitors
A Roulston, M Zimmermann, R Papp, A Skeldon… - Molecular cancer …, 2022 - AACR
Ataxia telangiectasia and Rad3-related (ATR) kinase protects genome integrity during DNA
replication. RP-3500 is a novel, orally bioavailable clinical-stage ATR kinase inhibitor …
replication. RP-3500 is a novel, orally bioavailable clinical-stage ATR kinase inhibitor …
Targeting the replication stress response through synthetic lethal strategies in cancer medicine
NYL Ngoi, MM Pham, DSP Tan, TA Yap - Trends in cancer, 2021 - cell.com
The replication stress response (RSR) involves a downstream kinase cascade comprising
ataxia telangiectasia-mutated (ATM), ATM and rad3-related (ATR), checkpoint kinases 1 and …
ataxia telangiectasia-mutated (ATM), ATM and rad3-related (ATR), checkpoint kinases 1 and …
hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic …
L Xu, X Ma, X Zhang, C Zhang, Y Zhang, S Gong… - Molecular Cancer, 2023 - Springer
Abstract Background Circular RNAs (circRNAs) play important roles in the occurrence and
development of cancer and chemoresistance. DNA damage repair contributes to the …
development of cancer and chemoresistance. DNA damage repair contributes to the …
Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies
C Stok, YP Kok, N van den Tempel… - Nucleic acids …, 2021 - academic.oup.com
Tumours with mutations in the BRCA1/BRCA2 genes have impaired double-stranded DNA
break repair, compromised replication fork protection and increased sensitivity to replication …
break repair, compromised replication fork protection and increased sensitivity to replication …